Unsurprisingly, romidepsin combined with PD1 antibody or romidepsin monotherapy was superior to PD1 antibody monotherapy or vehicle in the treatment of NK-T cell lymphoma, but the combination was not superior to romidepsin alone. The gene discussed is PDCD1; the disease is extranodal nasal NK/T cell lymphoma.